ストックスクリーナーアプリを入手
4.29
0.94%
0.04
アフターアワーズ：
4.29
Aquestive Therapeutics Inc (AQST) 最新ニュース
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... - Yahoo! Finance Canada
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026 - Investing.com Nigeria
Aquestive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aquestive Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-08-12 - seekingalpha.com
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings - MarketBeat
Aquestive Therapeutics Q2 Earnings Call Highlights - MarketBeat
AQST: Q2 revenue up 38%, Anaphylm resubmission on track, and launch preparations advancing - TradingView
Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Aquestive Therapeutics Q2 Loss Widens, Revenue Rises - Moomoo
Aquestive Plans to Take Epi Film Back to FDA with Positive Data - Allergic Living
Aquestive Therapeutics Latest Results: Sales guidance affirmed at $46-50M - scanx.trade
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Announces Q2 2026 Financial Results and Investor Presentation - Kalkine Media
Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Aquestive Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Aquestive Therapeutics (AQST) grows revenue and refinances debt in Q2 2026 - Stock Titan
Aquestive Therapeutics Q2 revenue beats on Suboxone strength - TradingView
Aquestive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-Aquestive Therapeutics, Inc. Q2 Revenue USD 13.819 Million Vs. IBES Estimate USD 11.4 Million - TradingView
Aquestive Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1%Here's Why - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 40% Downside - Yahoo Finance
Aquestive Therapeutics (NASDAQ:AQST): What Could Today’s Update Reveal About Regulatory Progress And Commercial Preparation? - Kalkine Media
Aquestive Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Form 8K Aquestive Therapeutics Inc For: 10 August By Investing.com - Investing.com Canada
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study - TradingView
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap UpShould You Buy? - MarketBeat
Anaphylm sublingual epinephrine film shows improved usability, comparable PK ahead of planned FDA resubmission - Contemporary Pediatrics
Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film - Moomoo
Aquestive Therapeutics shares jump after encouraging Anaphylm study results - Yahoo Finance
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside - GuruFocus
Aquestive Therapeutics' Potential Allergy Film Shows Improvements in Human Factors Study - marketscreener.com
Why is Aquestive Therapeutics stock surging today? By Investing.com - Investing.com Canada
Aquestive stock rises after Anaphylm study results By Investing.com - Investing.com Australia
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film - Investing News Network
Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Australia
Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials - Bitget
Aquestive reports study results for Anaphylm allergy treatment - Investing.com
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film - The Manila Times
Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026 - TradingView
Aquestive Therapeutics Announces Positive Topline Human - globenewswire.com
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
AQST STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Aquestive Therapeutics (AQST) Expected to Announce Earnings on Tuesday - MarketBeat
Aquestive Therapeutics to Report Second Quarter 2026 - GlobeNewswire
1.61%
1.30%
大文字化:
|
ボリューム (24 時間):